Regulatory considerations for successful implementation of digital endpoints in clinical trials for drug development.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 40044879.
- Also identified by DOI 10.1038/s41746-025-01513-5 and PMC identifier 11882986.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Regulatory acceptance of Digital Health Technology (DHT) -derived endpoints can be a long, multifaceted and costly process. Success relies on establishing a global strategy as part of the development program including health authority consultations to ensure alignment with regulatory requirements. In this manuscript, the authors provide stepwise guidance for successful implementation of DHT-derived endpoints in clinical trials for drug development.